Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Quince Therapeutics, Inc. terminated Finance Contract with European Investment Bank (EIB) valued at EUR 4,800,000, or approximately $5.5 million (effective 2026-03-27).
- Action
- termination
- Agreement
- credit facility
- Counterparty
- European Investment Bank (EIB)
- Value
- EUR 4,800,000, or approximately $5.5 million
- Effective
- 2026-03-27
Exact text from the filing
As previously disclosed, Quince Therapeutics, Inc. (the “Company”), Quince Therapeutics S.p.A. (the “Borrower”), the European Investment Bank (the “EIB”) and other parties named therein previously entered into a finance contract dated July 24, 2020 (as amended and restated, the “Finance Contract”) and a related guarantee agreement in connection with the Finance Contract (the “Guarantee Agreement,” together with the Finance Contract, the “Finance Documents”). On March 27, 2026, the Company agreed to pay, on the Borrower’s behalf, EUR 4,800,000, or approximately $5.5 million, to the EIB in full settlement of the Borrower’s obligations under the Finance Documents. As a result of the Company’s payment of such amount, the Company’s and the Borrower’s obligations under the finance documents were deemed satisfied.
View on SEC.gov